An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

@article{Wood2008AnAA,
  title={An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial},
  author={Christopher G Wood and Pramod Srivastava and Ronald A. Bukowski and Louis Lacombe and Andrei I Gorelov and S. V. Gorelov and Peter C R Mulders and Henryk Zieliński and A. M. Hoos and Florentina Teofilovici and Leah Isakov and Robert C. Flanigan and Robert J. Figlin and Renu Gupta and Bernard Escudier},
  journal={The Lancet},
  year={2008},
  volume={372},
  pages={145-154}
}
BACKGROUND Treatment of localised renal cell carcinoma consists of partial or radical nephrectomy. A substantial proportion of patients are at risk for recurrence because no effective adjuvant therapy exists. We investigated the use of an autologous, tumour-derived heat-shock protein (glycoprotein 96)-peptide complex (HSPPC-96; vitespen) as adjuvant treatment in patients at high risk of recurrence after resection of locally advanced renal cell carcinoma. METHODS In this open-label trial… CONTINUE READING
Highly Cited
This paper has 150 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 126 citations

150 Citations

01020'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 150 citations based on the available data.

See our FAQ for additional information.